In addition, local application of an AC133/CD133-specific T-cell-engaging antibody (a cancer stem cell marker) with human CD8+ T cells has been shown to prevent tumor outgrowth of subcutaneous GBM xenografts (8). The gene discussed is CD8A; the disease is glioblastoma.